Skip to main content

Table 2 Treatment response in biochemical or imageological patients

From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression

  Biochemical response (n, %) Imageological response (n, %) Overall response (n, %)
Complete response (CR) 0 (0%) 0 (0%) 0 (0%)
Partial response (PR) 5 (26.32%) 8 (36.36%) 13 (31.71%)
Stable disease (SD) 12 (63.16%) 7 (31.82%) 19 (46.34%)
Progressive disease (PD) 2 (10.53%) 7 (31.82%) 9 (21.95%)
Objective response rate (ORR) 5 (26.32%) 8 (36.36%) 13 (31.71%)
Disease control rate (DCR) 17 (89.47%) 15 (68.18%) 32 (78.05%)